Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Mar
07
Today In Oncology
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs
Cumulative Incidence of Advanced Breast Cancer in Japanese Women Aged 40 to 49 Years With Addition of Ultrasonography to Mammography Screening
HPV Vaccination Protection From Cervical Cancer Sustained Long Term
Five-Year Outcomes With First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma
FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo